Optimization of Crystallization Process of Azithromycin Dihydrate

化学工业与工程

Chemcial Industry and Engineering

2015, Vol. 32

Issue (1) :37-40 DOI: 10.13353/j.issn.1004.9533.2015.01.008

Article

Current Issue | Next Issue | Archive | Adv Search

<< | >>

Optimization of Crystallization Process of Azithromycin Dihydrate

Ma Boai¹, Gong Junbo^1,2

1. The State Research Center of Industrialization for Crystallization Technology, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China;
2. Key Laboratory Modern Drug Delivery and High Efficiency, Tianjin University, Tianjin 300072, China

Abstract	Reference	Related Articles

Download: PDF (1585KB) HTML () Export: BibTeX or EndNote (RIS) Supporting Info

Abstract In this paper, the influence of initial concentration, pumping rate of anti-solvent and agitation intensity on the crystal size distribution (CSD) of products was considered and then an optimized crystallization technology was proposed. The optimized products were obtained at 40 ℃ with 0.32 g/g initial concentration, 200 r/min agitation rate and 200 μL/min feeding rate. The CSD of products is from 300 μm to 800 μm and the mean crystal size is 580 μm.

	Service

	Email this article
	Add to my bookshelf
	Add to citation manager
	Email Alert
	RSS
	Articles by authors

Keywords： Azithromycin; dilution crystallization; crystal size distribution agg;lomeration

Received 2013-04-11;

About author:

Cite this article:

Ma Boai, Gong Junbo.Optimization of Crystallization Process of Azithromycin Dihydrate[J] Chemcial Industry and Engineering, 2015,V32(1): 37-40

[1]	鲍颖,王永莉,王静康. 溶析结晶研究进展[J]. 化学工业与工程, 2004, 21(6): 439-442 Bao Ying, Wang Yongli, Wang Jingkang. Process in dilution crystallization[J]. Chemical Industry and Engineering, 2004, 21(6): 439-442(in Chinese)
[2]	Gabrijela K, Gorjana L, Slobodan D, et al. Synthesis and antibacterial activity of O-methyl-azithromcyin derivatives[J].Antibiot.1992, 45(4):527-534
[3]	Peters D H, Friedel H A, McTavish D. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy[J]. Drugs, 1994, 44(5):754
[4]	Centellas V, Garcia R, Poch M, et al. Macrolides: WO, 0100640[P]. 2001-01-04
[5]	Yang Bingwei. Intermediate for azithromycin: WO, 9426758[P]. 1994-11-24
[6]	万献尧, 毕丽岩. 阿奇霉素[J].日本医学介绍.2004, 25(7):297-299
[7]	Allen D J M. Azithromycin dehydrate: EP,0298650[P]. 1989-01-11
[8]	Allen D J M. Azithromycin dehydrate: US,6268489[P]. 1992-12-21
[9]	Bright G M. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor: US,4474768[P]. 1982-11-15
[10]	张建州. 阿奇霉素的合成工艺研究[J].广州化工.2007, 35(2):34-26
[11]	Mullin J W. 结晶过程[M]. 大连: 大连理工大学出版社, 1991 Mullin J W. Crystallization[M]. Dalian: Dalian University of Technology Press, 1991
[12]	刘树宝. 5'-鸟苷酸二钠溶析结晶过程研究[D]. 天津: 天津大学, 2007 Liu Shubao. Study on crystallization process of disodium 5'-guanylate[D]. Tianjin: Tianjin University, 2007(in Chinese)
[13]	Tavare N S, Chivate M R. CSD analysis from a batch dilution crystallizer [J].J Chem Eng Jap.1980, 13(5):371-379
[14]	鲍颖. 盐酸大观霉素溶析结晶过程研究[D]. 天津: 天津大学, 2003 Bao Ying. Study on the process of dilution crystallization of spectinomycin dihydrochloride[D]. Tianjin: Tianjin University, 2003(in Chinese)
[15]	任国宾. 盐酸帕罗西汀结晶过程研究[D]. 天津: 天津大学, 2005 Ren Guobin. Study on the crystallization process of paroxetine hydrochloride[D]. Tianjin: Tianjin University, 2005(in Chinese)
[16]	Myerson A S. Handbook of industrial crystallization[M].2nd.America:Butterworth-Heinema Publisher, 2001
[17]	陆杰, 王静康. 反应结晶(沉淀)研究进展[J]. 化学工程, 1999, 27(4): 24-27 Lu Jie, Wang Jingkang. Study progress of reactive crystallization[J]. Chemical Engineering, 1999, 27(4): 24-27(in Chinese)
[18]	Heggie W, Zita M. Preparation of azithromycin: EP, 0879823 [P]. 1998-11-25